

## Editorial



# Journal of Lipid and Atherosclerosis Update 2024

## OPEN ACCESS

**Received:** Jan 4, 2024

**Accepted:** Jan 9, 2024

**Published online:** Jan 15, 2024

### Correspondence to

**Hyun Kang**

Department of Anesthesiology and Pain  
Medicine, Chung-Ang University College of  
Medicine, 84 Heukseok-ro, Dongjak-gu, Seoul  
06911, Korea.

Email: roman00@naver.com

**Copyright** © 2024 The Korean Society of Lipid  
and Atherosclerosis.

This is an Open Access article distributed  
under the terms of the Creative Commons  
Attribution Non-Commercial License ([https://  
creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/))  
which permits unrestricted non-commercial  
use, distribution, and reproduction in any  
medium, provided the original work is properly  
cited.

### ORCID iDs

Hyun Kang

<https://orcid.org/0000-0003-2844-5880>

### Funding

None.

### Conflict of Interest

Hyun Kang has been an Editor-in-Chief  
since 2023 of the Journal of Lipid and  
Atherosclerosis. However, he was not involved  
in the peer reviewer selection, evaluation,  
or decision process of this article. No other  
potential conflicts of interest relevant to this  
article were reported.

### Data Availability Statement

Data sharing is not applicable to this article  
as no datasets were generated or analyzed  
during the current study.

<https://e-jla.org>

**Hyun Kang**

Department of Anesthesiology and Pain Medicine, Chung-Ang University College of Medicine, Seoul, Korea

Not long ago, I addressed the “Message From the New Editor-in-Chief” upon assuming the role as the new Editor-in-Chief.<sup>1</sup> A year has swiftly transpired, witnessing unprecedented development in the *Journal of Lipid and Atherosclerosis (JLA)*. While certain changes have occurred, this editorial aims to elucidate some of these noteworthy developments.

Since *JLA* is indexed in PubMed in 2019 and in Scopus in 2020, *JLA* has developed to publish more than 30 high-qualified review, original article, brief report, letter to the editor and editorial in 2023. Authors from 5 countries published reviews and original articles in *JLA*.

The total number of citations has consistently increased, culminating in an estimated impact factor of 3.84 in the Journal Citation Reports (JCR) (estimated value at December 31, 2023). This places *JLA* in the second quartile (Q2) for the Biochemical Research Methods, Endocrinology & Metabolism, and Peripheral Vascular Disease categories (values are compared with JCR2022).

Additionally, the CiteScore Tracker 2022 (available from: [https://www.scopus.com/  
sourceid/21101032315](https://www.scopus.com/sourceid/21101032315)), calculated by Scopus, recorded a significant increase, reaching 6.5 as of December 6, 2022 (696 citations to date/107 documents to date). This is a substantial improvement from the CiteScore of 1.9 in 2021 and 5.1 in 2022.

The two most frequently cited articles delve into topics such as understanding and utilizing claim data<sup>2</sup> and Guidelines for the Management of Dyslipidemia.<sup>3</sup> While the impact factor is not a perfect measure and has faced criticism, it generally serves as an indicator of a journal's scientific impact. The editorial board acknowledges the limitations of the impact factor but is pleased with its rise, recognizing its potential to attract more quality submissions. Nevertheless, efforts will persist to enhance *JLA*'s impact factor, elevate its standing within the clinical and research community, and solidify its position as the premier journal in this field.

To achieve these objectives, the editorial board of *JLA* has actively engaged in soliciting recent and compelling research papers, fostering communication with the Korean Society of Lipid and Atherosclerosis, and collaborating with leading opinion groups in the field. Furthermore, key changes have been implemented in 2023: 1) Strengthening the journal's editorial and review capacity by inviting highly qualified editorial board members from 22 countries. 2) Enhancing transparency in the review process by revising or establishing data-sharing statements, preprint policies, disclosure of AI programs, and peer review processes. 3) The

submission system has been reorganized, making it more accessible for authors through the provision of *JLA* templates and endnote styles.

As we look forward, I hope *JLA* continues to evolve, and I invite you to enjoy the forthcoming year with *JLA*. Consider submitting your work or serving as a reviewer for the journal, and feel free to reach out with any questions or comments at [staff@e-jla.org](mailto:staff@e-jla.org).

## REFERENCES

1. Kang H. Message from the new Editor-in-Chief. *J Lipid Atheroscler* 2023;12:1. [PUBMED](#) | [CROSSREF](#)
2. Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) database for research. *J Lipid Atheroscler* 2022;11:103-110. [PUBMED](#) | [CROSSREF](#)
3. Cho SMJ, Lee H, Lee HH, Baek J, Heo JE, Joo HJ, et al. Dyslipidemia fact sheets in Korea 2020: an analysis of nationwide population-based data. *J Lipid Atheroscler* 2021;10:202-209. [PUBMED](#) | [CROSSREF](#)